WASHINGTON, D.C.-(BUSINESS WIRE)-October 20, 2020: The Fasano Longevity Conference, which will be held on November 2nd, will include a wide range of topics bearing on longevity markets, our health and the economy. The Conference will start this year with a Private Equity Investor’s Perspective on the Life Settlement Industry by Kurt Bolin, Principal of Stone [...]
Noted Economist to Discuss Economic Impact of Covid-19 at Fasano Conference Noted economist and fiscal policy expert, Eugene Steuerle, will discuss The Implications of Covid-19 for the Economy and Government Policy at the 2020 Fasano Life Settlement & Longevity Conference on Monday, November 2nd. [...]
Long-Term Mortality Impact of COVID-19 at Fasano Longevity Conference Andrew Cairns and Stuart McDonald will present their views on the Long-Term Mortality Impact of COVID-19 at the November 2nd Fasano Longevity Conference in Washington, DC. Dr. Cairns is Professor of Financial Mathematics at Heriot-Watt University in Edinburgh and [...]
Groundbreaking Geneticist to Keynote Fasano Longevity Conference Dr. Steve Horvath will deliver the Keynote Presentation on Epigenetics and Biomarkers: A New Age in Longevity Modeling at the November 2nd Fasano Longevity Conference in Washington, DC. Dr. Horvath, UCLA Professor in Human Genetics and Biostatistics, is the developer of [...]
THE 2020 FASANO LONGEVITY CONFERENCE: Private Equity Perspective on Life Settlements Kurt Bolin, Principal at Stone Point Capital, will present his views on the longevity and life settlement markets at the November 2nd Fasano Longevity Conference in Washington, DC. Stone Point Capital LLC is a [...]
THE 2020 FASANO LONGEVITY CONFERENCE: BEST VALUE EVER! Its Virtual: No cocktails or dinner this year; but we will make it feel real with live Q&A following every presentation All Substance: Our Agenda this year maintains Fasano's preeminence in delivering fresh, relevant presentations affecting the longevity markets. Topics will include: Epigenetics and Biomarkers: A [...]
The quality of life expectancy estimates is one key consideration for an investor in life settlements. The predominant metric for assessing this quality is the so-called A-to-E ratio, which relies on a comparison of the actual to the predicted number of deaths. In this article, we explain key issues with this metric: In the short [...]
This month we are publishing Actual to Expected performance results for our Structured Settlement underwriting business. The results are good, with an Actual to Expected ratio of 98% for the 2012 through 2016 period, assuming IBNR of 7%. Without IBNR, the A to E ratio would be 91%. But the real story here is not the results, [...]
